Study of Resistant Potato Starch Supplement for Adults with Cirrhosis and Hepatic Encephalopathy Four-Week Open-Label Treatment to Assess Gut Bacteria and Health Effects

What this Trial Is About

Researchers are studying how resistant potato starch, a dietary supplement made from potato starch, affects gut bacteria in people with cirrhosis and overt hepatic encephalopathy. The study aims to understand how this supplement works in the body and how the body responds to it. This research is led by Mayo Clinic and focuses on improving knowledge about gut health in this group of patients. Participants will take 20 grams of resistant potato starch twice daily for four weeks using Bobs Red Millae potato starch. There is no dose adjustment all participants receive the same amount. This is an open-label trial, meaning both participants and researchers know the treatment being given. During the study, participants will provide health information and stool samples. Researchers will measure changes in stool short-chain fatty acids, cognitive function through an animal naming test, gastrointestinal symptoms, and record any adverse events. The study will track adherence to the supplement and feasibility of completing study activities over eight weeks, with particular focus on changes from baseline to week four.

Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy